Bar graph shows the distribution of IM resistant CML patients according to the first line treatment and the total count at the time of diagnosis.

<p>As the WBC count increases, the difference between the lengths of the blue and the red bars increases to a greater extent as compared to the difference in lengths between the green and violet bars, indicating less number of mutations in patients pre-treated with a non-TKI (HU) as compared to the patients with first line imatinib.</p

Spectrum of mutations in the ABL KD and SH3-SH2 domain of BCR/ABL gene according to the disease phase.

<p>* Novel mutations detected</p><p>Spectrum of mutations in the ABL KD and SH3-SH2 domain of BCR/ABL gene according to the disease phase.</p

Kaplan-Meier survival curves according to the mutations and the disease phase.

<p>Group 1: Chronic Phase (P-Loop); Group 2: Chronic Phase (non P-Loop); Group 3: Accelerated Phase (P-Loop); Group 4: Accelerated Phase (non P-Loop); Group 5: Blast Crisis (P-Loop); Group 6: Blast Crisis (non P-Loop).</p

Diagram illustrating gradual disappearance of T315I mutation with hydroxyurea and spleenic irradiation treatment.

<p>Diagram illustrating gradual disappearance of T315I mutation with hydroxyurea and spleenic irradiation treatment.</p

Distribution of the patients according to their haematologic and cytogenetic response at the time of disease resistance.

<p>Frequency of mutations in patients with Haematologic resistance: 31/50 (62%)</p><p>Frequency of mutations in patients with cytogenetic resistance: 39/91 (43%)</p><p>CP: Chronic Phase</p><p>AP: Accelerated Phase</p><p>BC: Blast Crisis</p><p>CHR: complete Haematologic Response</p><p>CCyR: Complete Cytogenetic Response</p><p>n: Number of patients with mutations</p><p>N: Number of imatinib resistant patients</p><p>Distribution of the patients according to their haematologic and cytogenetic response at the time of disease resistance.</p

Clinical details of imatinib responders and non-responders.

<p>Clinical details of imatinib responders and non-responders.</p

Electropherogram showing the insertion mutation ΔCAGG at 303^th amino acid position between P-loop and gatekeeper region.

<p>Electropherogram showing the insertion mutation ΔCAGG at 303^th amino acid position between P-loop and gatekeeper region.</p